GBI Research analyzes the veterinary vaccines market up to 2017. The report examines the market by analyzing livestock species including bovine, ovine, equine and porcine. The target population considered is the total animal population in each respective region. The report specifically covers livestock species excluding companion animals, and concludes that the livestock market sector has shown steady growth in recent years. Biotechnology developments and research contributed tremendously towards the growth and enhancement of the veterinary vaccines market. Europe and the US collectively hold more than 70% of the total market.
The market grew at a steady rate for the past few years and is expected to grow further. The demand for veterinary vaccines in the market is driven by factors such as the vulnerability of animals to fatal and chronic diseases, and the changing patterns of the diseases. The recent epidemics created awareness among livestock owners of the need to avoid the huge production losses due to diseases such as swine flu, avian influenza and anthrax. The future of vaccines will be dominated by DNA-related vaccines and combination vaccines, which can provide protection against various diseases with minimal vaccine shots. Such innovative products will be more capable of providing protection and generating a strong immune response than the traditional vaccines.
The key players in the veterinary vaccines market are Bayer HealthCare, Merck & Co. Inc., Fort Dodge Animal Health, Novartis Animal Heath, Pfizer, Lohmann Animal Health, Merial Ltd., Boehringer Ingelheim GmbH, and Heska Corporation. There are many other companies which are involved with the manufacturing and development of veterinary vaccines apart from those in the list.
GBI Research, the leading business intelligence provider, has released its latest research, “Veterinary Vaccines Market to 2017 - Europe to Strengthen Its Position as the Single Largest Market for Animal Vaccines Due To Highly Organized Livestock Farms”. The report analyzes the markets for veterinary vaccines, covering bovine, ovine, porcine and equine species in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), and Japan. The report also provides geographical landscape, competitive landscape, product profiles, and analysis of drivers and barriers that impact the veterinary vaccines market. Furthermore, the report provides company profiling, SWOT analysis for the leading companies, and analysis of the mergers, acquisitions, recent activities and licensing agreements that shape the global markets.
The veterinary vaccines market has shown growth over recent years, which can be attributed to good animal husbandry practices and better management of farms. This results in the estimation of further growth in the market due to the advancement in biotechnological research and the tremendous development in the innovation of new vaccines for various diseases.
The global veterinary vaccines market grew at the rate of 1% from 2002-2010, and is likely to witness the same growth for the period 2011-2017. The European veterinary vaccines market grew at a CAGR of 1% from 2002 to 2010. The total livestock vaccines market was estimated to be worth $2.9 billion in 2010, and is expected to grow at the same rate to reach $3.1 billion in 2017.
As per the GBI Research analysis, Europe is expected to hold a major share in the veterinary vaccines market by 2017, with $3.1 billion in revenues, whereas the US market is estimated to reach $2.9 billion, contributing 48% to the total veterinary vaccines market.
The bovine vaccines market is the largest livestock vaccines market. In 2017, the market size for bovine vaccines is estimated to be $3 billion, out of which the US contributes $1.6 billion, Europe $1.3 billion, and Japan $70.4m. The market is expected to grow at the rate of 0.7% in the US and Europe.
The dairy and beef sectors are being converted into organized sectors in the developed countries, and a proper vaccination schedule is being followed. This is one of the main reasons for the growth in the bovine vaccines market.
The annual cost of vaccination (ACV) in the US was $12.9 for a cow-calf unit in 2002, and grew at a rate of 2.4% to reach $15.6 per cow-calf unit in 2010. A cow-calf unit refers to a unit which includes a cow with one or two calves. The ACV is estimated to grow from $15.6 to $17.6, at a CAGR of 2% for a cow-calf unit for the forecast period between 2010 and 2017.
The sheep vaccines market in the US grew at the rate of 13.7% from 2002 to 2010. The market was estimated at $22.1m in 2010, and is expected to grow at the rate of 4% from 2010 to 2017. The estimated market size in 2017 is $29.2m. This market is estimated to grow at the fastest rate (4%) among all the livestock vaccines markets. The sheep population in the US grew at a rate of 3% from 2002 to 2010. The total sheep population in the US was estimated at 3.2 million for 2010. The population is estimated to be 3.9 million by 2017. The population is expected to grow with the same rate for the next seven years.